Study of Pembrolizumab Combination Therapies in Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer (mCRPC). There will be ten cohorts